- [PRESSWIRE] Vienna – 30th June 2020 — Eveliqure Biotechnologies today announces that further financing has been secured from Arax Capital Partners comprising the last instalment of a €1.7M total investment provided by Arax. This is complemented by further private investment from Baobá and a Swiss based family office, and totals around €0.5M.
- [PRESSWIRE] Brussels – 2 June, 2020 — The EBRAINS shared Research Infrastructure for brain research is pleased to announce a significant step forward with the appointment of its founding CEO Paweł Świeboda. The EBRAINS digital brain research infrastructure is a key outcome of the European Commission’s Flagship 10-year research initiative Human Brain Project.
- [PRESSWIRE] Vienna – 4 June, 2020 — The Austrian biotech company CEBINA GmbH announces that it has received seed funding for its extended spectrum Coronavirus vaccine project, which is part of CEBINA’s broad-scale efforts offering short-, mid- and longer-term solutions to fight the COVID-19 pandemic. This seed funding will support proof-of-concept studies of the vaccine that will allow progress to pre-clinical development, scheduled for Q1/2021. The funds are provided by the Blom Family Office.
- [PRESSWIRE] Vienna – 2nd June 2020 — Eveliqure Biotechnologies today, announces that the Hungarian regulatory agency OGYÈI has approved the clinical trial for its vaccine program to prevent diarrhoeal diseases caused by Shigella and Enterotoxigenic E. coli (ETEC).
- [PRESSWIRE] Austria – 20 April, 2020 — Austrian biotech company Calyxha Biotechnologies GmbH is pleased to announce the grant of European Patent No. EP3383381. This patent covers the use of calixarene compounds for neurodegenerative diseases, including Parkinson’s disease. It represents the company’s first granted patent, with prosecution of the corresponding patent applications ongoing in other territories.
- [PRESSWIRE] HELSINKI – 16 April, 2020 — Karsa Oy, developer and manufacturer of chemical threat detectors for security applications, has launched a new business enterprise, Karsa Oy (Deutschland), in the Republic of Germany. Its innovative Chemical Ionization Mass Spectrometry technology was originally developed for climate change research and has been initially adapted for the detection of explosives in air cargo.
- [PRESSWIRE] Charlotte, NORTH CAROLINA – 30 March, 2020 — Over the past two weeks, the leading magazine for autism families rapidly responded to the changing needs of the autism community by providing sought after autism COVID-19 resources. Autism Parenting Magazine Editor-in-Chief Amy KD Tobik said coming together to develop tools such as social stories and visual schedules, along with professional advice, was critical.
- [PRESSWIRE] Chicago, IL United States – 19 March, 2020 — Surgisphere has developed a COVID-19 triage tool that helps prioritize care for patients who are in urgent need of care.
- [PRESSWIRE] Parma, Italy – March 12, 2020 — Kidney involvement seems to be frequent in patients who have tested positive for coronavirus. Acute kidney injury might be a predictor of mortality in infected patients.
- [PRESSWIRE] Parma – December 19, 2019 — The 2017 Annual Report of the ERA-EDTA Registry [1] reveals that only a small fraction of patients accepted for renal replacement therapy are able to start this treatment with the best available therapy, which is transplantation, – and that the number of people who are in need of renal replacement therapy is rising. This poses a major challenge to our health systems, therefore everything should be done to fight this trend, e.g. by strengthening prevention.
- [PRESSWIRE] France – 08 11 2019 -– In what represents a major milestone on the path to clinical application, a novel method to improve outcomes of Epilepsy surgery has now received approval for clinical testing in 13 French hospitals. The approach could provide a better therapeutic perspective against the drug-resistant form of the disease, which constitutes one third of all cases, and is a development by Human Brain Project scientist Viktor Jirsa and an interdisciplinary team of collaborators. To help clinicians plan surgery strategies, the scientists create personalized brain models of patients and simulate the spread of abnormal activity during epileptic seizures. The method represents the first example of a personalized brain modeling approach entering the clinic and will now be assessed over four years in a cohort of 356 patients under strict requirements.
- [PRESSWIRE] Dublin, Ireland – 09 December, 2019 — Workvivo will Provide Employee Engagement App. Irish employee engagement firm Workvivo has teamed up with US-based Seneca Gaming Corporation.
- [PRESSWIRE] Sochi, Russia – 24 October, 2019 — The Synthestech Company, has the pleasure to invite the international press and its members to a press conference entitled: A big step in the fight against aging.
- [PRESSWIRE] Squamish, B.C. – September 17, 2019 — Canadian clean energy company, Carbon Engineering Ltd. (CE), today announced it is expanding the capacity of the design for its first commercial Direct Air Capture (DAC) plant, to enable corporate customers to permanently remove carbon dioxide (CO2) emissions from the atmosphere.
- [PRESSWIRE] Budapest – June 13, 2019 — Alport syndrome (AS) is a hereditary type IV collagen disease that leads to progressive proteinuria, renal fibrosis, and kidney failure.
- [PRESSWIRE] Budapest – June 13, 2019 — High cardiovascular morbidity and mortality remain a persisting problem in patients with CKD. Many efforts have been made in subjects with normal kidney function to prevent and to reduce the progression of cardiovascular diseases.
- [PRESSWIRE] Parma – April 26, 2019 — The recently published CREDENCE study [1] showed that SGLT2 inhibitors can slow progression of chronic kidney disease (CKD) in diabetes patients in addition to the effects seen with RAAS blockade. The study results were presented at the World Nephrology Congress in Melbourne and showed that Canagliflozin was associated with a 34% risk reduction of the renal end point (end stage renal disease, doubling of serum creatinine or renal death). The previous day, the SONAR study had shown that the selective endothelin A receptor antagonist, atrasentan, reduced the risk of renal events in a specially selected CKD cohort with diabetes to a similar extent (35%).
- [PRESSWIRE] Parma – 05 March, 2019 — “Kidney health for everyone everywhere” – ERA-EDTA has helped to put this motto into practice by offering support for young nephrologists living in disadvantage areas.
- [PRESSWIRE] Parma – 05 March, 2019 — 850 million people worldwide are affected by kidney disease [1] – a worrying figure, and one that continues to rise. Prevention of chronic kidney disease is therefore more important than ever, as Professor Carmine Zoccali (Reggio Calabria, Italy), President of the ERA-EDTA, emphasizes on the occasion of World Kidney Day on March 14, 2019.
- [PRESSWIRE] Parma – January 22, 2019 — 16% of the patients on renal replacement therapy are under the age of 40. These younger patients would benefit greatly from kidney transplantation. Their expected remaining lifetime may even be doubled by having a transplant.
- [PRESSWIRE] ‘s-Hertogenbosch, The Netherlands – 5 July, 2018 — A total grant sum of EUR 2 million has been awarded to a multidisciplinary EUROSTARS consortium. The EUROSTARS project is titled “Treatment Response Monitoring for Cancer Immunotherapies Using Immune Repertoire Analysis” and named IMMUNOMONITOR.
- 2018年6月29日(星期五)即时发布 – 英国的 Cambridge Vacuum Engineering (CVE) 公司开发的新型局部真空电子束焊接技术正在推动发电领域发生革命性的变化。EB ManPower 项目是 CVE、U-Battery、Cammell Laird 和 TWI 的合作项目。
- [PRESSWIRE] 2018年6月29 日 即時リリース – イギリスのケンブリッジ・バキューム・エンジニアリング (CVE) 社が開発したローカル型真空電子ビーム溶接技術の新型モデルが発電産業の技術革新を支援しています。EB ManPower プロジェクトは、CVE、U-Battery、Cammell Laird、TWI が共同で取り組む事業です。
- [PRESSWIRE] Freitag, den 29. Juni 2018 – Eine von Cambridge Vacuum Engineering (CVE) im Vereinigten Königreich entwickelte neue lokale Vakuum-Elektronenstrahlschweißtechnologie stellt heute eine bahnbrechende neue Entwicklung im Stromerzeugungssektor dar. Das EB ManPower-Projekt ist eine Kooperation zwischen CVE, U-Battery, Cammell Laird und TWI.
- [PRESSWIRE] Пятница, 29е июня 2018 г. – Фундаментально новая технология электронно-лучевой сварки с использованием местного вакуума, разработанная в Соединенном Королевстве компанией Cambridge Vacuum Engineering (CVE), способствует революции в энергетическом секторе. В совместном проекте под названием EB ManPower участвуют компании CVE, U-Battery, Cammell Laird и TWI.
- [PRESSWIRE] Viernes 29 de junio de 2018 – Un nuevo y pionero tipo de tecnología de soldadura al vacío por haz de electrones local desarrollada en el Reino Unido por Cambridge Vacuum Engineering (CVE) está ayudando a revolucionar el sector de la generación de energía. El proyecto EB ManPower es una colaboración conjunta entre CVE, U-Battery, Cammell Laird y TWI.
- [PRESSWIRE] London, United Kingdom – 29 June, 2018 — CVE has developed a local vacuum EB welding system which can be readily transported and operated on site and applied to structures significantly larger than can be accommodated in a vacuum chamber.
- [PRESSWIRE] June 7, 2018 – Squamish, B.C. – Announced today, Carbon Engineering (CE), a Canadian-based clean energy company, has published new research that proves CO2 can now be captured from the atmosphere for less than $100USD per ton. Released in a peer-reviewed paper, CE’s breakthroughs in Direct Air Capture (DAC) technology demonstrate, for the first time, a scalable and cost-effective solution for removing CO2 from the atmosphere.
- [PRESSWIRE] London, United Kingdom – 14 March, 2018 — CVE has developed a local vacuum EB welding system which can be readily transported and operated on site and applied to structures significantly larger than can be accommodated in a vacuum chamber.
- [PRESSWIRE] London, United Kingdom – 02 February, 2018 — 真空チャンバーなしで電子ビーム溶接を実現できるこの新しいテクノロジーは、大規模な生産プロジェクトの効率性を向上させます。